Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

Coronary Artery Disease V: Interprofessional Care

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Deep Venous Dural Arteriovenous Fistula Mimicking Progressive Dementia.

Stroke·2026

Same author

Blood Pressure Management Following Endovascular Stroke Treatment: A Feasibility Trial and Meta-Analysis of Outcomes.

Stroke (Hoboken, N.J.)·2026

Same author

Efficacy and safety of intravenous nerinetide initiated by paramedics in the field for acute cerebral ischaemia within 3 h of symptom onset (FRONTIER): a phase 2, multicentre, randomised, double-blind, placebo-controlled study.

Lancet (London, England)·2025

Same author

Impact of the COVID-19 pandemic on outcomes of acute ischemic stroke patients treated with endovascular therapy: A multicenter Canadian study.

PloS one·2025

Same author

The value of MRI in transient ischemic attack/minor stroke following a negative CT for predicting subsequent stroke.

CJEM·2025

Same author

Combination Antithrombotic Therapy for Reduction of Recurrent Ischemic Stroke in Intracranial Atherosclerotic Disease.

Stroke·2025

Search research articles

Related Experiment Video

Updated: May 31, 2026

Ferric Chloride-induced Murine Thrombosis Models

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Antiplatelet agents for stroke prevention.

Samuel Yip¹, Oscar Benavente

¹Division of Neurology, Brain Research Centre, University of British Columbia, Stroke Program, Vancouver, British Columbia V5Z1M9, Canada. samyip100@gmail.com

Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics

|July 16, 2011

Summary

This summary is machine-generated.

Antiplatelet agents are crucial for secondary stroke prevention in noncardioembolic stroke patients. Early, lifelong treatment with aspirin, clopidogrel, or aspirin/dipyridamole is recommended, as combination therapy has not shown proven benefits.

More Related Videos

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

Related Experiment Videos

Last Updated: May 31, 2026

Ferric Chloride-induced Murine Thrombosis Models

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

Area of Science:

Neurology
Cardiology
Vascular Medicine

Background:

Stroke is a major cause of death and disability.
Ischemic stroke has diverse causes and mechanisms.
Stroke survivors face a high risk of recurrent vascular events.

Purpose of the Study:

To review the role of antiplatelet agents in secondary stroke prevention.
To evaluate the efficacy and safety of different antiplatelet therapies.
To provide guidance on optimal antiplatelet treatment strategies after ischemic stroke.

Main Methods:

Review of available data on antiplatelet agents for stroke prevention.
Analysis of evidence for combination therapy (aspirin plus clopidogrel).
Comparison of different antiplatelet monotherapies (aspirin, clopidogrel, aspirin/dipyridamole).

Main Results:

Antiplatelet agents are fundamental for secondary stroke prevention in noncardioembolic stroke.
Combination therapy (aspirin plus clopidogrel) is not proven effective or safe for early or long-term prevention.
No single antiplatelet agent demonstrates superiority for specific stroke subtypes.

Conclusions:

Aspirin, clopidogrel, or aspirin with extended-release dipyridamole are valid options for secondary stroke prevention.
Treatment initiation should be as early as possible.
Lifelong treatment with antiplatelet agents is recommended to maximize benefits.